Daniel A. Gipe

4.0k total citations · 3 hit papers
24 papers, 2.1k citations indexed

About

Daniel A. Gipe is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Cancer Research. According to data from OpenAlex, Daniel A. Gipe has authored 24 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Surgery, 14 papers in Cardiology and Cardiovascular Medicine and 11 papers in Cancer Research. Recurrent topics in Daniel A. Gipe's work include Lipoproteins and Cardiovascular Health (20 papers), Lipid metabolism and disorders (12 papers) and Cancer, Lipids, and Metabolism (10 papers). Daniel A. Gipe is often cited by papers focused on Lipoproteins and Cardiovascular Health (20 papers), Lipid metabolism and disorders (12 papers) and Cancer, Lipids, and Metabolism (10 papers). Daniel A. Gipe collaborates with scholars based in United States, Canada and Netherlands. Daniel A. Gipe's co-authors include Robert Pordy, Marie T. Baccara‐Dinet, John J.P. Kastelein, G. Kees Hovingh, Daniel Gaudet, Kuo‐Chen Chan, Poulabi Banerjee, Michel Farnier, Yunling Du and Henry N. Ginsberg and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Daniel A. Gipe

23 papers receiving 2.0k citations

Hit Papers

Evinacumab for Homozygous Familial Hypercholest... 2015 2026 2018 2022 2020 2015 2015 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Evinacumab for Homozygous Familial Hypercholesterolemia
    2020 470 citations Frederick J. Raal, Robert S. Rosenson et al. New England Journal of Medicine profile →
  2. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
    2015 418 citations John J.P. Kastelein, Henry N. Ginsberg et al. European Heart Journal profile →
  3. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
    2015 345 citations Patrick M. Moriarty, Paul D. Thompson et al. Journal of clinical lipidology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel A. Gipe United States 13 1.7k 736 577 573 447 24 2.1k
Claudia Stefanutti Italy 25 1.7k 1.0× 667 0.9× 276 0.5× 689 1.2× 439 1.0× 98 2.2k
Estella Kanevsky United States 10 1.8k 1.1× 659 0.9× 472 0.8× 554 1.0× 274 0.6× 15 2.1k
Christopher E. Kurtz United States 19 1.3k 0.8× 617 0.8× 483 0.8× 360 0.6× 207 0.5× 39 1.8k
Marie T. Baccara‐Dinet France 27 2.6k 1.5× 409 0.6× 1.1k 2.0× 585 1.0× 390 0.9× 59 2.8k
Helina Kassahun United States 15 1.7k 1.0× 524 0.7× 385 0.7× 338 0.6× 319 0.7× 30 2.1k
Patrick M. Moriarty United States 18 1.3k 0.8× 394 0.5× 332 0.6× 349 0.6× 282 0.6× 40 1.7k
Traci Turner United States 12 1.8k 1.1× 478 0.6× 568 1.0× 487 0.8× 430 1.0× 39 2.4k
Armando Lira Pineda United States 13 2.3k 1.4× 800 1.1× 594 1.0× 731 1.3× 368 0.8× 21 2.8k
Ransi Somaratne United States 15 3.0k 1.7× 597 0.8× 1.1k 1.9× 705 1.2× 432 1.0× 25 3.3k
Ransi Somaratne United States 22 3.1k 1.8× 655 0.9× 1.2k 2.1× 686 1.2× 459 1.0× 43 3.5k

Countries citing papers authored by Daniel A. Gipe

Since Specialization
Citations

This map shows the geographic impact of Daniel A. Gipe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Gipe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Gipe more than expected).

Fields of papers citing papers by Daniel A. Gipe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Gipe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Gipe. The network helps show where Daniel A. Gipe may publish in the future.

Co-authorship network of co-authors of Daniel A. Gipe

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel A. Gipe. A scholar is included among the top collaborators of Daniel A. Gipe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel A. Gipe. Daniel A. Gipe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Reeskamp, Laurens F., John S. Millar, WU Li-ya, et al.. (2021). ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report. Arteriosclerosis Thrombosis and Vascular Biology. 41(5). 1753–1759. 67 indexed citations
2.
Raal, Frederick J., Robert S. Rosenson, Laurens F. Reeskamp, et al.. (2020). Evinacumab for Homozygous Familial Hypercholesterolemia. New England Journal of Medicine. 383(8). 711–720. 470 indexed citations breakdown →
3.
Harada‐Shiba, Mariko, Shazia Ali, Daniel A. Gipe, et al.. (2020). A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. Atherosclerosis. 314. 33–40. 35 indexed citations
4.
Rosenson, Robert S., Frederick J. Raal, Laurens F. Reeskamp, et al.. (2020). The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolemia Patients with Little to No Low-Density Lipoprotein Receptor Activity. Journal of clinical lipidology. 14(4). 552–552. 1 indexed citations
5.
Moriarty, Patrick M., Jeffery M. Vance, Shazia Ali, et al.. (2020). Evaluating the effect of lipid-apheresis on evinacumab and angiopoietin-like 3 (ANGPTL3) levels. Atherosclerosis. 315. e37–e37. 1 indexed citations
6.
Banerjee, Poulabi, Kuo‐Chen Chan, Asier Benito‐Vicente, et al.. (2019). Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. Arteriosclerosis Thrombosis and Vascular Biology. 39(11). 2248–2260. 64 indexed citations
7.
Ahmad, Zahid, Poulabi Banerjee, Sara Hamon, et al.. (2019). Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. Circulation. 140(6). 470–486. 178 indexed citations
8.
Gaudet, Daniel, Daniel A. Gipe, Kees Hovingh, et al.. (2017). Safety and Efficacy of Evinacumab, A Monoclonal Antibody to ANGPTL3, In Homozygous Familial Hypercholesterolemia. Journal of clinical lipidology. 11(3). 837–838. 3 indexed citations
9.
10.
Dunbar, Richard L., Daniel A. Gipe, Robert Pordy, et al.. (2016). Abstract 19133: Inhibition of ANGPTL3 by Evinacumab Reduced Triglycerides (TGs) and LDL-C in Subjects Presenting With Modest Elevations in TGs and/or LDL-C, Recapitulating the Hypolipidemic Effects of Loss-of-Function (LoF) Mutations of ANGPTL3. Circulation. 134. 2 indexed citations
11.
Kastelein, John J.P., G. Kees Hovingh, Gisle Langslet, et al.. (2016). Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. Journal of clinical lipidology. 11(1). 195–203.e4. 56 indexed citations
12.
Gaudet, Daniel, Daniel A. Gipe, Robert Pordy, et al.. (2016). Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia receiving concomitant lipid-lowering therapies. Journal of clinical lipidology. 10(3). 715–715. 6 indexed citations
13.
Dufour, Robert, Jean Bergeron, Daniel Gaudet, et al.. (2016). Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment. International Journal of Cardiology. 228. 754–760. 15 indexed citations
14.
Kastelein, John J.P., Henry N. Ginsberg, Gisle Langslet, et al.. (2015). ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. European Heart Journal. 36(43). ehv370–ehv370. 418 indexed citations breakdown →
15.
Koren, Michael J., Eli M. Roth, James M. McKenney, et al.. (2015). Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis. Postgraduate Medicine. 127(2). 125–132. 15 indexed citations
16.
Moriarty, Patrick M., Paul D. Thompson, Christopher P. Cannon, et al.. (2015). Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. Journal of clinical lipidology. 9(6). 758–769. 345 indexed citations breakdown →
17.
Gaudet, Daniel, Dean J. Kereiakes, James M. McKenney, et al.. (2014). Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials). The American Journal of Cardiology. 114(5). 711–715. 167 indexed citations
18.
Moriarty, Patrick M., Terry A. Jacobson, Éric Bruckert, et al.. (2014). Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. Journal of clinical lipidology. 8(6). 554–561. 108 indexed citations
19.
Kastelein, John J.P., Jennifer G. Robinson, Michel Farnier, et al.. (2014). Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies. Cardiovascular Drugs and Therapy. 28(3). 281–289. 83 indexed citations
20.
Dufour, Robert, Evan A. Stein, Jean Bergeron, et al.. (2014). ONE YEAR OPEN-LABEL TREATMENT WITH ALIROCUMAB 150 MG EVERY TWO WEEKS IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS. Canadian Journal of Cardiology. 30(10). S338–S338.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claudia Stefanutti Breakdown of academic impact, for papers by Estella Kanevsky Breakdown of academic impact, for papers by Christopher E. Kurtz Breakdown of academic impact, for papers by Marie T. Baccara‐Dinet Breakdown of academic impact, for papers by Helina Kassahun Breakdown of academic impact, for papers by Patrick M. Moriarty Breakdown of academic impact, for papers by Traci Turner Breakdown of academic impact, for papers by Armando Lira Pineda Breakdown of academic impact, for papers by Ransi Somaratne Breakdown of academic impact, for papers by Ransi Somaratne
Rankless by CCL
2026